Related Experiment Videos
Summary
Chemotherapy, particularly alkylating agents, can increase the risk of secondary acute myeloid leukemia. While a concern, these vital treatments should not be withheld from patients with serious diseases.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Increasing reports link chemotherapy to secondary acute myeloid leukemia (AML).
- This occurs in patients treated for various cancers and non-neoplastic diseases.
- Both chemotherapy and radiotherapy have been implicated, but chemotherapy alone is also a factor.
Purpose of the Study:
- To review the association between cytotoxic agents and secondary malignancies.
- To inform clinical practice regarding the risks and benefits of chemotherapy.
- To address the potential reluctance in using chemotherapy due to secondary cancer risks.
Main Methods:
- Literature review of reported cases of secondary neoplasms.
- Analysis of drugs most frequently associated with secondary leukemia.
- Examination of the frequency of this syndrome in patient series.
Main Results:
- Alkylating agents, procarbazine, and nitrosoureas are frequently implicated in secondary AML.
- The incidence of secondary AML ranges from less than 1% to 7% in reported series.
- Patients receiving significant chemotherapy benefit may have a higher risk of adverse consequences.
Conclusions:
- Cytotoxic agents are a significant cause of secondary acute myeloid leukemia.
- The risk of secondary leukemia should be considered but not prevent the use of chemotherapy when it is the best treatment.
- Caution is advised when using these agents for non-neoplastic conditions like rheumatoid arthritis.